Company Profile
Syndax Pharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Syndax Pharmaceuticals is an oncology company focused on targeted therapies and hematologic disease opportunities. Investors watch trial readouts, regulatory milestones, and how the company converts its pipeline into commercial traction.
Geographic Base and Sector Classification
Headquartered in Waltham, Massachusetts and listed on NASDAQ, Syndax is followed within the oncology universe for its exposure to catalyst-driven development and launch events.
Business Model Characteristics
Syndax follows a pipeline-and-launch model where data quality, approval timing, and market access determine how quickly the company can scale.
Position Within the Biotechnology Landscape
Compared with larger oncology peers, Syndax sits closer to the development side of the landscape, where each major update can move expectations quickly.
Why the stock is moving
SNDX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Syndax's catalysts are Revuforj and Niktimvo commercial execution, plus any hematology or oncology update that broadens the story. The company improves when product revenue keeps compounding.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
Source: Syndax Pharmaceuticals
- 02
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Source: Syndax Pharmaceuticals
- 03
- 04
- 05
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
Source: Syndax Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.